Trauma-informed, Resilience-based Telehealth Intervention for Improving HIV Prevention and HCV Care for Persons Who Inject Drugs in the Deep South (Pilot Testing: Aim3)

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Georgia

About this trial

Evaluate the feasibility, acceptability, and usability of the intervention (primary outcomes) and coping skills and resilience (secondary outcomes) of the telehealth intervention over two months (8 weekly sessions) in a waitlist-controlled, randomized pilot trial using a cross-over design among 40 PWID. The primary outcomes will be feasibility, acceptability, and usability of the intervention. Secondary outcomes will be increased coping skills and resilience, which in turn, will increase status neutral HIV and HCV care and MOUD uptake (longer-term outcomes). Outcomes will be assessed using pre- and post-intervention surveys.

Eligibility criteria

Qualifiers

People who actively inject drugs verified by visible injection stigmata (needle tracks)

HIV negative

Adult (≥18 years)

lives in rural areas

Disqualifiers

Living with HIV

Lives in urban areas

Not proficient in English

Trial design

Treatments tested in this trial

  • Telehealth Behavioral Intervention for promoting HIV and HCV care and MOUD among Persons who inject drugs (PWID)

Treatment groups

50 Participants
are divided into 2 treatment groups

Sponsors and collaborators

University of Georgia

Lead sponsor

National Institute on Drug Abuse (NIDA)

Collaborator